Synthetic Cannabinoids in the United States

PURPOSE: This report provides up-to-date information regarding the status of synthetic cannabinoid prevalence and positivity in the United States.

OVERVIEW: Novel psychoactive substances (NPS), including synthetic cannabinoids, continue to pose great challenges for forensic scientists, clinicians, and public health and safety personnel. Synthetic cannabinoids have been implicated in an increasing number of emergency room admissions, death investigations, and intoxication events in corrections populations. Maintaining a current scope of analysis can be challenging, requiring comprehensive analytical methodologies and reference materials for identification(s).

OBJECTIVE: Our laboratory utilizes novel approaches for the analysis of drugs in biological samples and seized materials using comprehensive non-targeted data acquisition by gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). The scope of analysis contains more than 1,100 drugs, including a vast majority of NPS and their metabolites. This approach allows for real-time identification of novel synthetic cannabinoids and further data analysis of important trends. This project was conducted in collaboration with the toxicology and criminalistics laboratories of NMS Labs. Forensic case types linked to these results include illicit drug investigations, medicolegal death investigations, and/or driving under the influence of drugs (DUID) investigations. The results in this report represent the total number of NPS identifications at the CFSRE during this quarter, including those from sample-mining, data-mining, and/or esoteric testing.

SYNTHETIC CANNABINOIDS IDENTIFIED

<table>
<thead>
<tr>
<th>Toxicology</th>
<th>Drug Material</th>
</tr>
</thead>
<tbody>
<tr>
<td>5F-MDMB-PICA</td>
<td>1</td>
</tr>
<tr>
<td>ADB-BINACA (ADB-BUTINACA)</td>
<td>1</td>
</tr>
<tr>
<td>MDMB-4en-PINACA</td>
<td>4</td>
</tr>
</tbody>
</table>

SELECT POSITIVITY: Q4 2020 to Q3 2023

NPS IN Q3 2023:
- Opioids
- Benzodiazepines
- Stimulants & Hallucinogens
- Synthetic Cannabinoids

NOTABLE SYNTHETIC CANNABINOIDS TO MONITOR
- MDMB-BINACA (MDMB-BUTINACA) + Metabolites
- MDMB-PICA, MDMB-PINACA, + Others
- MDMB-5‘Me-INACA + Related Final Products (e.g., MDMB-5‘Me-PINACA)

TREND REPORT Q3 2023

ACNOWLEDGEMENTS: This report was prepared by Alex J. Krotulski, PhD; Sara E. Walton, MS; Amanda L.A. Kohr, MSFS; D-ABFT-F1; and Barry K. Logan, PhD, F-ABFT at the Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation. CFSRE’s NPS Discovery program acknowledges scientists at the CFSRE and NMS Labs for their involvements and contributions. For more information about our programs and reports, please contact NPS Discovery at npsdiscovery@cfsre.org or visit our website at www.npsdiscovery.org.

FUNDING: CFSRE’s NPS Discovery is supported by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice (Award Number 15PNIJ-22-GC-04454-MUMU, “Implementation of NPS Discovery – An Early Warning System for Novel Drug Intelligence, Surveillance, Monitoring, Response, and Forecasting using Drug Materials and Toxicology Populations in the US”). The opinions, findings, conclusions and/or recommendations expressed in this publication are those of the author(s) and do not necessarily represent the official position or policies of the U.S. Department of Justice.